[1] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[2] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|
[3] |
ZHANG Dousheng, WANG Chen, XU Mingzhe.
Rapid evaluation of potential neurotoxicity of levornidazole for injection and its main impurities based on computational models and database technology
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 712-716.
|
[4] |
ZHENG Yi, GUO Xiaojing, XU Jinfang, GUO Zhijian, CHI Lijie, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Analysis of adverse reactions of ibrutinib with information component method
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1228-1232.
|
[5] |
CHI Lijie, CHEN Chenxin, ZHENG Yi, WEI Lianhui, CHEN Xiao, GUO Zhijian, GUO Xiaojing, HE Jia, YE Xiaofei.
Applications of International Spontaneous Reporting System Databases
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1144-1147.
|
[6] |
FAN Rong, DONG Duo.
Overview and Thoughts on WHO International Drug Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 43-46.
|
[7] |
HU Fangyuan, YE Xiaofei, ZHAI Yinghong, XU Jinfang, GUO Xiaojing, GUO Zhijian, ZHUANG Yonglong, HE Jia.
Drug-associated Toxicities of Cemiplimab: A Real-world Study Based on FARES Database
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 480-486.
|
[8] |
YANG Shubin, PEI Chenchen, SHI Wei, WANG Xin, LI Na, CAO Guangshang, ZHANG Haiming, NIE Yinglan, SUN Jian.
Network Pharmacology Study of Chinese Medicine Guizhifuling Formulae
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 214-220.
|
[9] |
SHEN Zhuojie, XU Jinfang, YE Xiaofei, JIA Zheyu, LIANG Jizhou, WANG Meng, GUO Xiaojing.
Current Status of Pharmacovigilance Research Based on Administrative Claims Database
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 129-133.
|
[10] |
WAN Bangxi, YU Lina, XU Juping.
Data Quality of Individual Case Safety Reports Based on ICH E2B (R3) Implementation Guidelines
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(10): 597-601.
|
[11] |
WANG Tao, WANG Dan, FAN Yan, DONG Duo.
Upgrade of EudraVigilance in the EU and Its Considerations
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(7): 411-413.
|
[12] |
WU Nan, YANG Yue.
Inspiration from EU EndraVigilance
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 230-233.
|
[13] |
LIN Hong-bo, LIU Cui-li, SHEN Peng, LI Hai-long, ZHAO Hou-yu, ZHAN Si-yan.
Analysis of Ribavirin Utilization Based on Yinzhou Healthcare Database
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 73-77.
|
[14] |
HOU Yong-fang, SHEN Lu, LIU Wei, SONG Hai-bo, LIU Cui-li, WANG Dan, LI Xin-ling.
Medical Product Active Surveillance System in America and Its Revelation
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 32-35.
|
[15] |
ZHANG Yuan, YE Xiao-fei, ZHANG Tian-yi, ZHU Tian-tian, SHI Wen-tao, HE Jia.
Foreign Pharmaceautical Enterprises' Pharmacovigilance Databases Overview and Enlightenments
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 590-592.
|